HSBC upgraded Lupin (LUPN.NS) to 'overweight' from 'neutral', saying the drug maker's July-September earnings were higher than expected, while shares had under-performed peers over the past three months.
HSBC also raised its target price to 650 rupees from 640 rupees, adding Lupin is seeing "healthy" sales across regions, while highlighting near-term launches in the drug maker's U.S. pipeline.
The drug maker on Tuesday said its July-September quarter net profit rose 9 percent to 2.91 billion rupees.
Lupin shares fell 0.3 percent to 561.15 rupees at 0348 GMT.
0 comments:
Post a Comment
Let Us Know Your Opinion!